Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 24 | -1.13 Increased by +13.74% | -1.20 Increased by +5.83% |
| Feb 22, 24 | -1.39 Decreased by -10.32% | -0.88 Decreased by -57.95% |
| Nov 7, 23 | -1.03 Increased by +20.16% | -0.77 Decreased by -33.77% |
| Aug 1, 23 | -1.12 Increased by +31.29% | -0.44 Decreased by -154.55% |
| May 15, 23 | -1.31 Increased by +28.80% | -1.63 Increased by +19.63% |
| Mar 8, 23 | -1.26 Increased by +68.50% | -0.92 Decreased by -36.96% |
| Nov 9, 22 | -1.29 Increased by +26.70% | -1.32 Increased by +2.27% |
| Aug 9, 22 | -1.63 Increased by +18.50% | -1.65 Increased by +1.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -8.57 T Decreased by -238.07 M% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -9.02 M Decreased by -7.64% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.82 M Increased by +9.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -6.19 M Increased by +28.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.60 M Increased by +63.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -8.38 M Increased by +60.66% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -8.59 M Increased by +6.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -8.64 M Increased by +18.37% | Decreased by N/A% Decreased by N/A% |